EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Infant acute lymphoblastic leukaemia—Progress from worldwide clinical efforts

Neil Barrett iD, Tanja A Gruber, Takako Miyamura iD, Alasdair Duguid iD, Janine Stutterheim iD

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70166 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Neil Barrett und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Children's Health Ireland, Dublin, Ireland. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 101 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infant acute lymphoblastic leukaemia (ALL) is a rare and aggressive type of leukaemia, especially when a KMT2A rearrangement is involved. Historical treatment strategies have included intensification of conventional ALL chemotherapy in combination with acute myeloid leukaemia treatment elements. However, outcomes have remained consistently poor compared to the advances that have been seen in childhood ALL. The emergence of novel immunotherapies has transformed treatment strategies, with blinatumomab now incorporated into clinical trials for infants with KMT2A ‐rearranged ALL, promising significant advancements. Additionally, deeper insights into the unique biology of KMT2A ‐rearranged ALL have facilitated the development of targeted therapies, such as venetoclax and menin inhibitors, which are under clinical evaluation. These efforts offer renewed hope for better outcomes. This review highlights the substantial progress in understanding and treating K MT2A ‐rearranged ALL, fuelling optimism for future therapeutic success. In addition, we highlight the challenges that might be faced by using immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaHumansInfantMyeloid-Lymphoid Leukemia ProteinImmunotherapyHistone-Lysine N-MethyltransferaseAntibodies, BispecificGene RearrangementMolecular Targeted TherapyBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

KMT2A‐rearrangedacute lymphoblastic leukaemiainfant

Substanzen

Myeloid-Lymphoid Leukemia ProteinKMT2A protein, humanHistone-Lysine N-MethyltransferaseAntibodies, BispecificBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Haematology, Children's Health Ireland, Dublin, Ireland.
  • Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
  • Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.

ORCID-Profile: Neil Barrett, Takako Miyamura, Alasdair Duguid, Janine Stutterheim

Zitieren

APA

Barrett, N., Gruber, T. A., Miyamura, T., Duguid, A., & Stutterheim, J. (2025). Infant acute lymphoblastic leukaemia—Progress from worldwide clinical efforts. British Journal of Haematology. https://doi.org/10.1111/bjh.70166

Vancouver

Barrett N, Gruber TA, Miyamura T, Duguid A, Stutterheim J. Infant acute lymphoblastic leukaemia—Progress from worldwide clinical efforts. British Journal of Haematology. 2025. doi:10.1111/bjh.70166

BibTeX
@article{Barrett2025,
  author = {Barrett, Neil and Gruber, Tanja A and Miyamura, Takako and Duguid, Alasdair and Stutterheim, Janine},
  title = {Infant acute lymphoblastic leukaemia—Progress from worldwide clinical efforts},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70166}
}
Kostenlos starten →